Chu-Huang Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3118329/publications.pdf

Version: 2024-02-01

257357 223716 2,414 68 24 citations h-index papers

g-index 68 68 68 2850 docs citations times ranked citing authors all docs

46

#	Article	IF	Citations
1	Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. European Heart Journal, 2021, 42, 1797-1807.	1.0	58
2	Adiponectin forms a complex with atherogenic LDL andÂinhibits its downstream effects. Journal of Lipid Research, 2021, 62, 100001.	2.0	13
3	Electronegative very-low-density lipoprotein induces brain inflammation and cognitive dysfunction in mice. Scientific Reports, 2021, 11, 6013.	1.6	5
4	Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies. Journal of Clinical Medicine, 2021, 10, 1992.	1.0	5
5	Electronegative lowâ€density lipoprotein of patients with metabolic syndrome induces pathogenesis of aorta through disruption of the stimulated by retinoic acidÂ6 cascade. Journal of Diabetes Investigation, 2020, 11, 535-544.	1.1	3
6	Nociceptive transient receptor potential canonical 7Â(TRPC7) mediates agingâ€associated tumorigenesis induced by ultraviolet B. Aging Cell, 2020, 19, e13075.	3.0	18
7	An Increased Plasma Level of ApoCIII-Rich Electronegative High-Density Lipoprotein May Contribute to Cognitive Impairment in Alzheimer's Disease. Biomedicines, 2020, 8, 542.	1.4	6
8	Clinical Significance of Electronegative Low-Density Lipoprotein Cholesterol in Atherothrombosis. Biomedicines, 2020, 8, 254.	1.4	12
9	Effect of acyl and alkyl analogs of platelet-activating factor on inflammatory signaling. Prostaglandins and Other Lipid Mediators, 2020, 151, 106478.	1.0	9
10	Increased APOE glycosylation plays a key role in the atherogenicity of L5 lowâ€density lipoprotein. FASEB Journal, 2020, 34, 9802-9813.	0.2	15
11	Association of Electronegative LDL with Macrophage Foam Cell Formation and CD11c Expression in Rheumatoid Arthritis Patients. International Journal of Molecular Sciences, 2020, 21, 5883.	1.8	11
12	Atherogenic L5 LDL induces cardiomyocyte apoptosis and inhibits KATP channels through CaMKII activation. Lipids in Health and Disease, 2020, 19, 189.	1.2	2
13	Detection of a High Ratio of Soluble to Membraneâ€Bound LOXâ€1 in Aspirated Coronary Thrombi From Patients With STâ€5egment–Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014008.	1.6	15
14	Role of Lowâ€Density Lipoprotein in Early Vascular Aging Associated With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 972-984.	2.9	22
15	Role of apolipoprotein E in electronegative low-density lipoprotein-induced mitochondrial dysfunction in cardiomyocytes. Metabolism: Clinical and Experimental, 2020, 107, 154227.	1.5	13
16	Combined LDL and VLDL Electronegativity Correlates with Coronary Heart Disease Risk in Asymptomatic Individuals. Journal of Clinical Medicine, 2019, 8, 1193.	1.0	10
17	Immunoregulatory effects of very low density lipoprotein from healthy individuals and metabolic syndrome patients on glial cells. Immunobiology, 2019, 224, 632-637.	0.8	5
18	Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy. BMJ Open Diabetes Research and Care, 2019, 7, e000661.	1.2	23

#	Article	lF	CITATIONS
19	Very Low-Density Lipoproteins of Metabolic Syndrome Modulates STIM1, Suppresses Store-Operated Calcium Entry, and Deranges Myofilament Proteins in Atrial Myocytes. Journal of Clinical Medicine, 2019, 8, 881.	1.0	11
20	An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. International Journal of Molecular Sciences, 2019, 20, 1149.	1.8	433
21	A potential new approach for treating systemic sclerosis: Dedifferentiation of SSc fibroblasts and change in the microenvironment by blocking store-operated Ca2+ entry. PLoS ONE, 2019, 14, e0213400.	1.1	5
22	A Novel Cell-Free, Non-Fluorescent Method to Measure LOX-1-Binding Activity Corresponding to The Functional Activity of HDL. Journal of Atherosclerosis and Thrombosis, 2019, 26, 947-958.	0.9	9
23	Association between Negatively Charged Low-Density Lipoprotein L5 and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients. Journal of Clinical Medicine, 2019, 8, 177.	1.0	13
24	Xanthine-derived KMUP-1 reverses glucotoxicity-activated Kv channels through the cAMP/PKA signaling pathway in rat pancreatic l ² cells. Chemico-Biological Interactions, 2018, 279, 171-176.	1.7	9
25	Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF. Journal of Lipid Research, 2018, 59, 2063-2074.	2.0	22
26	Range of L5 LDL levels in healthy adults and L5's predictive power in patients with hyperlipidemia or coronary artery disease. Scientific Reports, 2018, 8, 11866.	1.6	18
27	Human electronegative LDL induces mitochondrial dysfunction and premature senescence of vascular cells in vivo. Aging Cell, 2018, 17, e12792.	3.0	39
28	Hydrogen gas protects IP3Rs by reducing disulfide bridges in human keratinocytes under oxidative stress. Scientific Reports, 2017, 7, 3606.	1.6	11
29	Electronegative LDL-mediated cardiac electrical remodeling in a rat model of chronic kidney disease. Scientific Reports, 2017, 7, 40676.	1.6	6
30	VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis. Cancer Letters, 2017, 388, 130-138.	3.2	83
31	Electronegative Low-Density Lipoprotein L5 Induces Adipose Tissue Inflammation Associated With Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4615-4625.	1.8	15
32	Very-Low-Density Lipoprotein of Metabolic Syndrome Modulates Gap Junctions and Slows Cardiac Conduction. Scientific Reports, 2017, 7, 12050.	1.6	21
33	Human electronegative low-density lipoprotein modulates cardiac repolarization via LOX-1-mediated alteration of sarcolemmal ion channels. Scientific Reports, 2017, 7, 10889.	1.6	5
34	Electronegative low-density lipoprotein increases the risk of ischemic lower-extremity peripheral artery disease in uremia patients on maintenance hemodialysis. Scientific Reports, 2017, 7, 4654.	1.6	10
35	The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications. Trends in Cardiovascular Medicine, 2017, 27, 239-246.	2.3	21
36	VLDL from Metabolic Syndrome Individuals Enhanced Lipid Accumulation in Atria with Association of Susceptibility to Atrial Fibrillation. International Journal of Molecular Sciences, 2016, 17, 134.	1.8	12

3

#	Article	IF	Citations
37	Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. Medicine (United States), 2016, 95, e2265.	0.4	12
38	Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation. Blood, 2016, 127, 1336-1345.	0.6	69
39	Age-dependent impact of new ESC-Guideline recommended door-to-balloon times on mid-term survival in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. International Journal of Cardiology, 2016, 222, 242-246.	0.8	9
40	Update on ADAMTS13 and VWF in cardiovascular and hematological disorders. Clinica Chimica Acta, 2016, 463, 109-118.	0.5	32
41	Electronegative low density lipoprotein induces renal apoptosis and fibrosis: STRA6 signaling involved. Journal of Lipid Research, 2016, 57, 1435-1446.	2.0	15
42	Enhanced Sphingomyelinase Activity Contributes to the Apoptotic Capacity of Electronegative Low-Density Lipoprotein. Journal of Medicinal Chemistry, 2016, 59, 1032-1040.	2.9	19
43	Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis. Clinical Chemistry, 2016, 62, 320-327.	1.5	102
44	Four Statin Benefit Groups Defined by The 2013 ACC/AHA New Cholesterol Guideline are Characterized by Increased Plasma Level of Electronegative Low-Density Lipoprotein. Acta Cardiologica Sinica, 2016, 32, 667-675.	0.1	8
45	Sesamol Reduces the Atherogenicity of Electronegative L5 LDLin Vivoandin Vitro. Journal of Natural Products, 2015, 78, 225-233.	1.5	28
46	(PS) ² : protein structure prediction server version 3.0. Nucleic Acids Research, 2015, 43, W338-W342.	6. 5	45
47	Increased LDL electronegativity in chronic kidney disease disrupts calcium homeostasis resulting in cardiac dysfunction. Journal of Molecular and Cellular Cardiology, 2015, 84, 36-44.	0.9	22
48	Low-Density Lipoprotein Electronegativity Is a Novel Cardiometabolic Risk Factor. PLoS ONE, 2014, 9, e107340.	1.1	23
49	The Underlying Chemistry of Electronegative LDL's Atherogenicity. Current Atherosclerosis Reports, 2014, 16, 428.	2.0	20
50	Gender disparity in LDL-induced cardiovascular damage and the protective role of estrogens against electronegative LDL. Cardiovascular Diabetology, 2014, 13, 64.	2.7	15
51	Mesenchymal Stem Cell Derived Exosomes: A New Hope for the Treatment of Cardiovascular Disease?. Acta Cardiologica Sinica, 2014, 30, 395-400.	0.1	17
52	Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovascular Research, 2013, 99, 137-145.	1.8	48
53	Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation. Blood, 2013, 122, 3632-3641.	0.6	69
54	Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor. PLoS ONE, 2013, 8, e70533.	1.1	39

#	Article	IF	CITATIONS
55	Effects of Electronegative VLDL on Endothelium Damage in Metabolic Syndrome. Diabetes Care, 2012, 35, 648-653.	4.3	29
56	The Most Negatively Charged Low-Density Lipoprotein L5 Induces Stress Pathways in Vascular Endothelial Cells. Journal of Vascular Research, 2012, 49, 329-341.	0.6	22
57	Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 1009-1018.	2.2	26
58	Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein. Pure and Applied Chemistry, 2011, 83, 1731-1740.	0.9	27
59	Mediation of Electronegative Low-Density Lipoprotein Signaling by LOX-1. Circulation Research, 2009, 104, 619-627.	2.0	127
60	Electronegative LDL Impairs Vascular Endothelial Cell Integrity in Diabetes by Disrupting Fibroblast Growth Factor 2 (FGF2) Autoregulation. Diabetes, 2008, 57, 158-166.	0.3	65
61	Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. Journal of Lipid Research, 2008, 49, 33-47.	2.0	73
62	Electronegative LDL disrupts mitochondrial homeostasis: a novel mechanism for cigarette smokingâ€associated endothelial dysfunction. FASEB Journal, 2008, 22, 471.12.	0.2	0
63	Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis, 2007, 193, 283-291.	0.4	32
64	Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application. Current Vascular Pharmacology, 2004, 2, 33-43.	0.8	64
65	Platelet-activating factor acetylhydrolase: is it good or bad for you?. Current Opinion in Lipidology, 2004, 15, 337-341.	1.2	51
66	Low-Density Lipoprotein in Hypercholesterolemic Human Plasma Induces Vascular Endothelial Cell Apoptosis by Inhibiting Fibroblast Growth Factor 2 Transcription. Circulation, 2003, 107, 2102-2108.	1.6	147
67	Isolation, Characterization, and Functional Assessment of Oxidatively Modified Subfractions of Circulating Low-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1083-1090.	1.1	98
68	Inhibitory Effects of Hypercholesterolemia and Ox-LDL on Angiogenesis-like Endothelial Growth in Rabbit Aortic Explants. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1303-1312.	1.1	73